Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model.

[1]  P. Coric,et al.  CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins , 1997, Psychopharmacology.

[2]  Brigitte L. Kieffer,et al.  Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene , 1996, Nature.

[3]  H. Steiner,et al.  Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin , 1996, Nature.

[4]  B. Roques,et al.  The Dual Peptidase Inhibitor RB101 Induces a Long‐Lasting Increase in the Extracellular Level of Met‐Enkephalin‐Like Material in the Nucleus Accumbens of Freely Moving Rats , 1996, Journal of neurochemistry.

[5]  B. Roques,et al.  Implication of endogenous opioid system in the learned helplessness model of depression , 1995, Pharmacology Biochemistry and Behavior.

[6]  S. Lukas,et al.  Buprenorphine treatment of refractory depression. , 1995, Journal of clinical psychopharmacology.

[7]  R. Maldonado,et al.  Participation of opioid and monoaminergic mechanisms on the antinociceptive effect induced by tricyclic antidepressants in two behavioural pain tests in mice , 1994, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[8]  B. Roques,et al.  Effect of mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalin degrading enzymes on a model of depression in the rat , 1993, Biological Psychiatry.

[9]  M. Fournié-Zaluski,et al.  Unlike morphine the endogenous enkephalins protected by RB101 are unable to establish a conditioned place preference in mice. , 1993, European journal of pharmacology.

[10]  M. Fournié-Zaluski,et al.  Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes, RB101. , 1992, European journal of pharmacology.

[11]  J. Gillin,et al.  Association of beta-endorphin with specific clinical symptoms of depression. , 1992, The American journal of psychiatry.

[12]  F Noble,et al.  "Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes. , 1992, Journal of medicinal chemistry.

[13]  M. Fournié-Zaluski,et al.  Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation. , 1992, European journal of pharmacology.

[14]  S. Turcaud,et al.  In vivo occupation of mouse brain opioid receptors by endogenous enkephalins: blockade of enkephalin degrading enzymes by RB 101 inhibits [3H]diprenorphine binding , 1992, Brain Research.

[15]  J. Slangen,et al.  Animal Models in Psychopharmacology , 1991, APS: Advances in Pharmacological Sciences.

[16]  G. Di Chiara,et al.  (D-Ala2)deltorphin II: D1-dependent stereotypies and stimulation of dopamine release in the nucleus accumbens , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[17]  B. Roques,et al.  Improved quantitative radioautography of rat brain δ-opioid binding sites using [3H]DSTBULET, a new highly potent and selective linear enkephalin analogue , 1990, Neurochemistry International.

[18]  B. Roques,et al.  Synthesis, biochemical and pharmacological properties of BUBUC, a highly selective and systemically active agonist for in vivo studies of δ-opioid receptors , 1990, Peptides.

[19]  I. Kitchen,et al.  Antagonism of swim‐stress‐induced antinociception by the δ‐opioid receptor antagonist naltrindole in adult and young rats , 1990, British journal of pharmacology.

[20]  J. Féger,et al.  Chronic blockade of D2 but not D1 dopamine receptors facilitates behavioural responses to endogenous enkephalins, protected by kelatorphan, administered in the accumbens in rats , 1990, Neuropharmacology.

[21]  J. Fuentes,et al.  Antidepressant action of imipramine and iprindole in mice is enhanced by inhibitors of enkephalin-degrading peptidases. , 1989, European journal of pharmacology.

[22]  M. E. Lewis,et al.  Anatomy of CNS opioid receptors , 1988, Trends in Neurosciences.

[23]  B. Roques,et al.  Development of conformationally constrained linear peptides exhibiting a high affinity and pronounced selectivity for delta opioid receptors. , 1988, Journal of medicinal chemistry.

[24]  S. Daenen,et al.  CURE OF PSEUDOMONAS AERUGINOSA INFECTION IN NEUTROPENIC PATIENTS BY CONTINUOUS INFUSION OF CEFTAZIDIME , 1988, The Lancet.

[25]  B. Roques,et al.  [3H][D-Ser2(O-tert-butyl),Leu5]enkephalyl-Thr6 and [D-Ser2(O-tert-butyl),Leu5]enkephalyl-Thr6(O-tert-butyl). Two new enkephalin analogs with both a good selectivity and a high affinity toward delta-opioid binding sites. , 1988, The Journal of biological chemistry.

[26]  N. Nair,et al.  The effect of electroconvulsive therapy on endorphins in depression , 1988, Biological Psychiatry.

[27]  P. Soubrié,et al.  Reversal of helpless behavior in rats by putative 5-HT1A agonists , 1988, Biological Psychiatry.

[28]  P. Portoghese,et al.  Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist , 1988 .

[29]  E. Hamel,et al.  Neutral endopeptidase-24.11, μ and δ opioid receptors after selective brain lesions: an autoradiographic study , 1987, Brain Research.

[30]  T. Shippenberg,et al.  Motivational properties of opioids: evidence that an activation of σ-receptors mediates reinforcement processes , 1987, Brain Research.

[31]  M. Hamon,et al.  Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline , 1987, Neuropharmacology.

[32]  J. Glowinski,et al.  Further evidence for a role of delta-opiate receptors in the presynaptic regulation of newly synthesized dopamine release. , 1986, European journal of pharmacology.

[33]  K. Isenberg,et al.  Possible involvement of opiate receptors in the pharmacological profiles of antidepressant compounds. , 1984, European journal of pharmacology.

[34]  P. Kalivas,et al.  Enkephalin action on the mesolimbic system: a dopamine-dependent and a dopamine-independent increase in locomotor activity. , 1983, The Journal of pharmacology and experimental therapeutics.

[35]  M. Zimmermann,et al.  Ethical guidelines for investigations of experimental pain in conscious animals , 1983, Pain.

[36]  J. Rossier,et al.  β‐ENDORPHIN IMMUNOREACTIVITY IN THE PLASMA OF PSYCHIATRIC PATIENTS RECEIVING ELECTROCONVULSIVE TREATMENT * , 1982, Annals of the New York Academy of Sciences.

[37]  S. Maier,et al.  The nature of the activity deficit produced by inescapable shock , 1982 .

[38]  F. Petty,et al.  Specificity of the learned helplessness model of depression , 1982, Pharmacology Biochemistry and Behavior.

[39]  J. Weiss,et al.  Behavioral depression produced by an uncontrollable stressor: Relationship to norepinephrine, dopamine, and serotonin levels in various regions of rat brain , 1981, Brain Research Reviews.

[40]  Douglas L. Jones,et al.  From motivation to action: Functional interface between the limbic system and the motor system , 1980, Progress in Neurobiology.

[41]  W. Bunney,et al.  PLASMA OPIOID ACTIVITY IN MANIC-DEPRESSIVE ILLNESS , 1980, The Lancet.

[42]  A. Biegon,et al.  Interaction of tricyclic antidepressants with opiate receptors. , 1980, Biochemical pharmacology.

[43]  J. Holaday,et al.  The opiate antagonist naloxone modifies the effects of electroconvulsive shock (ECS) on respiration, blood pressure and heart rate , 1979, Brain Research.

[44]  M. Fischler,et al.  beta-Endorphin-like immunoreactivity in cerebrospinal fluid and plasma of patients with schizophrenia and other neuropsychiatric disorders. , 1979, Pharmakopsychiatrie, Neuro-Psychopharmakologie.

[45]  A. Lajtha,et al.  Beta-endorphine-induced changes in schizophrenic and depressed patients N.S. Kline, C.H. Li, H.E. Lehmann, A. Lajtha, E. Laski and T. Cooper, Arch. gen. Psychiat., 34 (1977) 1111–1113 , 1979, PAIN.

[46]  A. Lajtha,et al.  β-Endorphin-Induced Changes in Schizophrenic and Depressed Patients , 1977 .

[47]  M. Seligman,et al.  Learned helplessness: Theory and evidence. , 1976 .

[48]  S. Maier,et al.  Influence of control of shock on subsequent shock-elicited aggression. , 1972, Journal of comparative and physiological psychology.

[49]  D. Naber.  Opioids in the Etiology and Treatment of Psychiatric Disorders , 1993 .

[50]  J. Micó,et al.  Relationship Between Emotivity Level and Susceptibility to the Learned Helplessness Model of Depression in the Rat , 1991 .

[51]  P. Willner.  Animal models of depression: an overview. , 1990, Pharmacology & therapeutics.

[52]  T. Kameyama,et al.  Inhibition of enkephalin degradation attenuated stress-induced motor suppression (conditioned suppression of motility). , 1988, The Journal of pharmacology and experimental therapeutics.

[53]  S. Maier,et al.  Learned helplessness, inactivity, and associative deficits: effects of inescapable shock on response choice escape learning. , 1980, Journal of experimental psychology. Animal behavior processes.